$220.10
▼ -0.3% Today
as of Sep 4, 16:46 ET
Last 30 days
Recent Press Releases & News
mixed
▲ 3
● 22
▼ 0
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Piper Sander Adjusts Biogen Price Target to $245 From $225, Maintains Overweight Rating
Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. Patients
Overview
52-week range
$135
$226
94% of range
Avg surprise (last 2)
+15.9%
Avg reaction (last 1)
-0.1%
0% positive
Latest IV / EM
37%
EM ±1.5% · $225 · Sep 4
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $2.15 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $3.17 | — | — | — | — | financials |
| Thu Jul 31, 2025 | Jun/2025 | $5.47 | $3.93 | +39.2% | — | — | earnings |
| Thu May 1, 2025 | Mar/2025 | $3.02 | $3.26 | -7.4% | — | -0.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $2.66 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $4.00 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $2.70 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.47 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $4.07 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $2.67 | — | — | — | — | financials |
| Fri Sep 30, 2022 | Sep 2022 | $7.84 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.48B | — | $2.53B | $2.65B | $2.43B | — | $2.47B | $2.46B |
| Cost of revenue | $661M | — | $674M | $605M | $629M | — | $639M | $546M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | $320M | — | $466M | $635M | $240M | — | $388M | $584M |
| EPS (diluted) | $2.15 | — | $3.17 | $4.33 | $1.64 | — | $2.66 | $4.00 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | — | — | — | — | — | — |
| Inventory | $1.95B | $2.17B | $2.21B | $2.27B | $2.27B | $2.46B | $2.47B | $2.51B |
| Total current assets | $9.19B | $8.97B | $8.94B | $7.97B | $7.63B | $7.46B | $6.83B | $7.11B |
| Total assets | $29.48B | $29.44B | $29.21B | $28.33B | $28.03B | $28.05B | $28.31B | $26.80B |
| Long-term debt | $6.29B | $6.29B | $6.29B | $6.28B | $4.55B | $4.55B | $4.55B | $6.29B |
| Total liabilities | $10.83B | $11.18B | $11.00B | $10.70B | $11.05B | $11.33B | $11.95B | $10.91B |
| Total equity | $18.65B | $18.26B | $18.21B | $17.63B | $16.98B | — | $16.36B | $15.89B |